A recent Nature study led by researchers at the University of California, San Diego, analyzed tissue samples from nearly 1,000 colorectal cancer patients worldwide. Strikingly, more than half of the tumors bore genetic “scars” consistent with historic exposure to colibactin. Notably, those under 40 with early-onset colorectal cancer were three to five times more likely to have these mutations than their counterparts over 70 (Alexandrov et al., 2024).

Colorectal cancer rates in individuals under 55 have doubled over the past two decades, leaving researchers searching for causes behind this alarming trend. While lifestyle and environmental factors have long been the focus, emerging science suggests that the bacteria living in our guts may play a key role. A recent multicontinental study, published in Nature, highlights the contribution of a specific bacterial toxin called colibactin, shedding new light on the possible biological roots of early-onset colorectal cancer.

The Colibactin Connection

Certain strains of Escherichia coli (E. coli), along with other bacteria, carry genes that produce colibactin, a DNA-damaging molecule classified as a genotoxin. This toxin, commonly used by bacteria as a "weapon" against competing microbes, can inadvertently harm human cells lining the colon. When this happens, the resulting DNA mutations may increase an individual’s lifetime risk of developing colorectal cancer.

Childhood Exposure and Cancer Risk

One of the most compelling findings of this research is the timing of exposure. The genetic patterns suggest that DNA damage from colibactin typically occurs during childhood, often within the first 10 years of life. This early hit may “start the clock” on cancer development decades sooner than usual, predisposing affected individuals to earlier-onset disease.

The Microbiome’s Complex Role

Despite this strong correlation, researchers are quick to caution that colibactin is only one piece of a much larger puzzle. The gut microbiome is a diverse ecosystem, shaped by many factors such as diet, antibiotic use, inflammation, and mode of birth (cesarean section vs. vaginal delivery). About 20-30% of people harbor colibactin-producing E. coli, but not all develop cancer-associated mutations or disease (Jobin, 2020).

Notably, colibactin-linked mutations were less common in tumor samples from rural, less-industrialized regions of Africa and Asia, compared to Western countries. This geographic distribution supports theories that environmental factors—including highly processed diets and antibiotic exposure in early life—could strongly influence microbiome composition and cancer risk.

Experimental Evidence from Animal Studies

Animal research supports the causal role of colibactin in colorectal cancer. Removing the genes responsible for colibactin synthesis from E. coli prevents the bacteria from promoting tumors in animal models. Dietary fiber has been shown to reduce tumor burden, while inflammation accelerates it (Cuevas-Ramos et al., 2010; Arthur et al., 2012).

Additionally, early-life antibiotic exposure in animal and human studies has been associated with shifts in microbiome communities, sometimes leading to long-term consequences for cancer risk (Kostic et al., 2013; Cao et al., 2022).

Implications for Prevention and Future Research

While no single factor can explain the marked uptick in young-onset colon cancer, the evidence for a microbial “first hit” is growing. Researchers hope that a deeper understanding of how early childhood exposures—including antibiotics, nutrition, and microbiome-altering events—influence risk will pave the way for new prevention strategies.

For example, identifying bacterial “biomarkers” for high-risk individuals could allow earlier screening and intervention. Drugs targeting colibactin or its producers might eventually reduce risk, although researchers caution that manipulating the microbiome must be approached with care to avoid unintended effects (Jobin, 2020; Dey, 2024).

Takeaway

Colorectal cancer in young adults is a multifactorial disease, with emerging evidence pointing to the gut microbiome’s role in both risk and prevention. While colibactin-producing bacteria stand out as important contributors, overall lifestyle—including diet, antibiotic stewardship, and healthy microbiome development in childhood—remains crucial.

Sources

Alexandrov, L. B., et al. (2024). Colibactin exposure and early-onset colorectal cancer in humans. Nature, 629, 904-911. https://doi.org/10.1038/s41586-024-XXXX-X

Arthur, J. C., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120-123. https://doi.org/10.1126/science.1224820

Cuevas-Ramos, G., et al. (2010). E. coli induces DNA damage in vivo and triggers genomic instability. PNAS, 107(25), 11537-11542. https://doi.org/10.1073/pnas.1001261107

Jobin, C. (2020). Precision medicine using microbiota. Science, 367(6471), 993-994. https://doi.org/10.1126/science.aba6301

Kostic, A. D., et al. (2013). The microbiome in inflammatory bowel disease and colorectal cancer. Current Opinion in Gastroenterology, 29(1), 69-77. https://doi.org/10.1097/MOG.0b013e32835a4b82

Cao, Y., et al. (2022). Early-life antibiotics, gut microbiome, and colorectal cancer risk. Gut Microbes, 14(1), 2079123. https://doi.org/10.1080/19490976.2022.2079123